{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:00:21Z","timestamp":1790874021353,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disorder involving degeneration of dopaminergic neurons in the substantia nigra, abnormal aggregation of \u03b1-synuclein, and neuroinflammatory response. Although research on PD immunotherapy is advancing rapidly, bibliometric analysis in this field remains underdeveloped.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Literature related to \u201cParkinson\u2019s disease\u201d and \u201cimmunotherapy\u201d from the Web of Science Core Collection and Scopus was used for data merging and bibliometric analysis via Bibliometrix. The characteristics of the relevant clinical trials in this field retrieved from the PubMed database were summarized, and the study protocols were traced back through the trials registry website.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After merging the two databases, a total of 890 documents from 488 sources were covered. A total of 3,804 researchers from 1,483 institutions in 63 countries published research in this field. Authors, institutions, and countries\/regions were classified into 5, 12, and 13 clusters, respectively. Keywords such as \u201cParkinson\u2019s disease\u201d, \u201cimmunotherapy\u201d, and \u201calpha-synuclein\u201d were frequently used. The maps of keyword co-occurrence and clusters revealed the generation of two clusters. A total of 8 clinical trials were searched and included. These trials focused on active immunotherapy and targeted antibodies, involving both healthy volunteers and patients with PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The field of PD immunotherapy has vigorous development potential. The current research focus in this field is concentrated on analyzing pathological mechanisms and innovating treatment strategies. Precise immunological intervention techniques are frontiers in this field. In the future, large-scale randomized controlled trials should be conducted to enhance the clinical translation efficiency of immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1659848","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:56:15Z","timestamp":1759996575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Research on Parkinson\u2019s disease immunotherapy: a bibliometric analysis via multiple databases"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinxing","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102136","article-title":"Phytomolecules from conventional to nano form: Next-generation approach for Parkinson\u2019s disease","volume":"93","author":"Pradhan","year":"2024","journal-title":"Ageing Res Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12051117","article-title":"Escalating bi-directional feedback loops between proinflammatory microglia and mitochondria in ageing and post-diagnosis of parkinson\u2019s disease","volume":"12","author":"Ravenhill","year":"2023","journal-title":"Antioxidants (Basel Switzerland)."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.1583-22.2022","article-title":"Modulation of motor vigor by expectation of reward probability trial-by-trial is preserved in healthy ageing and parkinson\u2019s disease patients","volume":"43","author":"Tecilla","year":"2023","journal-title":"J neuroscience: Off J Soc Neurosci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00646-5","article-title":"Recombinant antibody fragments for immunotherapy of parkinson\u2019s disease","volume":"38","author":"Manoutcharian","year":"2024","journal-title":"BioDrugs: Clin immunotherapeutics biopharmaceuticals Gene Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.357903","article-title":"Neuro faces of beneficial T cells: essential in brain, impaired in aging and neurological diseases, and activated functionally by neurotransmitters and neuropeptides","volume":"18","author":"Levite","year":"2023","journal-title":"Neural regeneration Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29294","article-title":"Clues to reshaping anti-\u03b1-synuclein immunotherapy in early parkinson\u2019s disease patients","volume":"38","author":"Palermo","year":"2023","journal-title":"Movement disorders: Off J Movement Disord Society."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29016","article-title":"A randomized first-in-human study with UB-312, a UBITh\u00ae \u03b1-synuclein peptide vaccine","volume":"37","author":"Yu","year":"2022","journal-title":"Movement disorders: Off J Movement Disord Society."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/pharmaceutics15030770","article-title":"Current treatments and new, tentative therapies for parkinson\u2019s disease","volume":"25","author":"Pardo-Moreno","year":"2023","journal-title":"Pharmaceutics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.17574","article-title":"A call for the establishment of bibliometric reporting guidelines","volume":"34","author":"Fei","year":"2024","journal-title":"J Clin nursing."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1292587","article-title":"A bibliometric analysis of cerebral palsy from 2003 to 2022","volume":"15","author":"Hu","year":"2024","journal-title":"Front neurology."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v14.i11.1755","article-title":"Near-infrared spectroscopy in schizophrenia: A bibliometric perspective","volume":"14","author":"Fei","year":"2024","journal-title":"World J Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jan.16233","article-title":"Emotional labour in nursing research: A bibliometric analysis","volume":"81","author":"Zhang","year":"2025","journal-title":"J advanced nursing."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2017.08.007","article-title":"bibliometrix: An R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetrics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102818","article-title":"Targeting autophagy in doxorubicin-induced cardiotoxicity: A comprehensive review of scientific landscapes and therapeutic innovations","volume":"110","author":"Wang","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103380","article-title":"Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson\u2019s disease","volume":"67","author":"Olson","year":"2021","journal-title":"EBioMedicine."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Movement disorders: Off J Movement Disord Society."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-synuclein antibody lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Movement disorders: Off J Movement Disord Society."},{"key":"B19","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1124\/jpet.124.002199","article-title":"Quantification of cinpanemab (BIIB054) binding to \u03b1-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples","volume":"392","author":"Liu","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurology."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.2952","article-title":"Sensitive electrochemical recognition of \u03b1-synuclein protein in human plasma samples using bioconjugated gold nanoparticles: An innovative immuno-platform to assist in the early stage identification of Parkinson\u2019s disease by biosensor technology","volume":"36","author":"Aminabad","year":"2023","journal-title":"J Mol recognition: JMR."},{"key":"B22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tem.2022.01.003","article-title":"Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson\u2019s disease: (Trends in Endocrinology & Metabolism 33, 147-157; 2022)","volume":"34","author":"Anis","year":"2023","journal-title":"Trends Endocrinol metabolism: TEM."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.neuron.2024.05.003","article-title":"Nuclear aggregates of NONO\/SFPQ and A-to-I-edited RNA in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"112","author":"Belur","year":"2024","journal-title":"Neuron."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-240002","article-title":"Parkinson\u2019s disease and dementia with lewy bodies: one and the same","volume":"14","author":"Borghammer","year":"2024","journal-title":"J Parkinson\u2019s disease."},{"key":"B26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13024-023-00686-5","article-title":"and motor deficits in the \u03b1-synuclein transgenic mouse model of Parkinson\u2019s disease","volume":"18","author":"Geng","year":"2023","journal-title":"Mol neurodegeneration."},{"key":"B27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11481-025-10227-0","article-title":"The dopaminergic and anti-neuroinflammatory properties of functionalized nanoliposomes containing levodopa and ibuprofen and conjugated with anti-alpha-synuclein aptamer","volume":"20","author":"Mostafa-Tehrani","year":"2025","journal-title":"J neuroimmune pharmacology: Off J Soc NeuroImmune Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102114","article-title":"Exploring Parkinson-associated kinases for CRISPR\/Cas9-based gene editing: beyond alpha-synuclein","volume":"92","author":"Mansour","year":"2023","journal-title":"Ageing Res Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c05864","article-title":"Ultrasound-assisted CRISPRi-exosome for epigenetic modification of \u03b1-synuclein gene in a mouse model of parkinson\u2019s disease","volume":"18","author":"Kong","year":"2024","journal-title":"ACS nano."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/med.22091","article-title":"\u03b1-synuclein in parkinson\u2019s disease: from bench to bedside","volume":"45","author":"Bellini","year":"2025","journal-title":"Medicinal Res Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02119-x","article-title":"FoxO1 alleviates the mitochondrial ROS levels induced by \u03b1-synuclein preformed fibrils in BV-2 microglial cells","volume":"48","author":"Na","year":"2025","journal-title":"Inflammation."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413451","article-title":"Microglia process \u03b1-synuclein fibrils and enhance their pathogenicity in a TREM2-dependent manner","volume":"12","author":"Xiong","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)."},{"key":"B33","doi-asserted-by":"publisher","first-page":"309:122622","DOI":"10.1016\/j.biomaterials.2024.122622","article-title":"Iron ions-sequestrable and antioxidative carbon dot-based nano-formulation with nitric oxide release for Parkinson\u2019s disease treatment","author":"Guo","year":"2024","journal-title":"Biomaterials."},{"key":"B34","doi-asserted-by":"publisher","first-page":"20632","DOI":"10.1038\/s41598-023-48067-8","article-title":"The effects of safinamide according to gender in Chinese parkinsonian patients","volume":"13","author":"Pellecchia","year":"2023","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-212594","article-title":"Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early parkinson\u2019s disease: A randomized, placebo-controlled, phase 1 study","volume":"11","author":"Poewe","year":"2021","journal-title":"J Parkinson\u2019s disease."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurology."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100661","article-title":"Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson\u2019s disease","volume":"3","author":"Karayel","year":"2022","journal-title":"Cell Rep Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ane.12590","article-title":"Cerebrospinal fluid biomarkers for Parkinson\u2019s disease - a systematic review","volume":"135","author":"Andersen","year":"2017","journal-title":"Acta neurologica Scandinavica."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1037068","article-title":"Bibliometric analysis of research on Alzheimer\u2019s disease and non-coding RNAs: Opportunities and challenges","volume":"14","author":"Fei","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/jpr.S436457","article-title":"Bibliometric analysis of research on traditional chinese exercise and osteoarthritis","volume":"17","author":"Zeng","year":"2024","journal-title":"J Pain Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2024.103111","article-title":"A bibliometric analysis of acupuncture for Parkinson\u2019s disease non-motor symptoms from 2003 to 2023","volume":"87","author":"Wang","year":"2024","journal-title":"Complementary therapies Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1659848\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:56:16Z","timestamp":1759996576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1659848\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1659848"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1659848","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"1659848"}}